Audrey Sarry

Comparison of venetoclax and azacitidine versus a cytarabine‐based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real‐world study of the DATAML ‐ IPC ‐ AURAML consortium

Pierre‐Yves Dumas, Sarah Bertoli, Emilie Bérard, Clémence Santana et autres

Complete remission (CR) rates for patients with acute myeloid leukaemia (AML) treated with intensive chemotherapy (IC) have increasingly improved. Yet, relapse remains a concern with a dismal prognosis. In this report, results are presented of a retrospective analysis comparing salvage therapy based …

fr (code pays fourni par la source)

Treatment Modalities and the Impact of Granulocyte Colony-Stimulating Factor in AML Patients Treated With Venetoclax and Azacitidine: A DATAML Registry Study

Léopoldine Lapierre, Lucie Laemmel, Emilie Bérard, Lucie Rigolot et autres

Azacitidine-venetoclax (AZA-VEN) has become a standard treatment in older or chemotherapy-ineligible AML patients. While the registration trial showed a median overall survival (OS) of 14.7 months, most real-world studies have not reproduced this result. We analyzed treatment patterns, adverse events, responses and …

fr, lb (code pays fourni par la source)

Characteristics of patients diagnosed for acute myeloid leukemia before and during the 2020 COVID-19 pandemic: the DATAML population-based cohort

Sébastien Lamy, R. Fenni, S. Tavitian, Léopoldine Lapierre et autres

Literature shows heterogeneous impact of recommendations to deal with sars-cov-2 infection on AML management during the 2020 Covid-19 pandemic. Available French data only rely on monocentric observations or simulations. From the DATAML cohort, including all AML patients cared for in the centers …

fr (code pays fourni par la source)

Post-induction minimal residual disease assessment by flow cytometry and molecular biology enables prognostic stratification of patients with NPM1-mutated Acute Myeloid Leukemia: A dataml registry study.

Jean Vial, Inès Vergnolle, Laëtitia Largeaud, Lucie Donaty et autres

Abstract IntroductionMRD assessment in AML provides a quantitative approach to define a deeper remission status and refine the risk assessment of postremission relapse. Currently, the two most extensively validated methodologies are multiparameter flow cytometry-based MRD (MFC-MRD) and molecular MRD (Mol-MRD) assessed by …

fr (code pays fourni par la source)

Salvage-free, transplantation-free survival (STFS) in AML: Proposition for a novel clinical endpoint to better assess the efficacy of novel drugs in combination with intensive chemotherapy. a dataml registry study.

Christian Récher, Emilie Bérard, Suzanne Tavitian, Thibaut Leguay et autres

Abstract IntroductionResults from pivotal clinical trials evaluating the combination of intensive chemotherapy (IC) with inhibitors of IDH1, IDH2, menin, FLT3 and BCL2 are expected in the coming years. These results could transform the therapeutic landscape for AML patients (pts) fit for IC. …

fr (code pays fourni par la source)

Levofloxacin to Prevent Bacterial Infection in Patients With Acute Myeloid Leukemia Treated by Venetoclax and Azacitidine: A Toulouse-Bordeaux DATAML Registry Study

Xavier Brousse, Nicolas Rasandisona, Emilie Bérard, Harmony Leroy et autres

Abstract Objectives Antibiotic prophylaxis for patients with cancer remains a controversial issue and is not broadly recommended for hematological malignancies. The venetoclax (VEN) and azacitidine (AZA) combination allows for high rates of complete remission in acute myeloid leukemia (AML) but enhances the …

fr, nl (code pays fourni par la source)

Mini‐consolidations or intermediate‐dose cytarabine for the post‐remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries

Christian Récher, Pierre‐Yves Dumas, Emilie Bérard, Suzanne Tavitian et autres

Abstract According to current recommendations, older AML patients in first complete remission (CR) after induction chemotherapy should receive consolidation with intermediate‐dose cytarabine (IDAC). However, no study has demonstrated the superiority of IDAC over other regimen. In this retrospective study, we compared the …

fr, de (code pays fourni par la source)

Data-driven flow cytometry classification of blast differentiation in older patients with acute myeloid leukemia

Catia Patricia Simoes, Carmen González, François Vergez, Audrey Sarry et autres

es, fr (code pays fourni par la source)

Mini-consolidations or intermediate-dose cytarabine (IDAC) for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries.

Christian Récher, Pierre‐Yves Dumas, Emilie Bérard, Suzanne Tavitian et autres

fr, ca, de, gb (code pays fourni par la source)

Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study

Camille Gondran, Pierre‐Yves Dumas, Emilie Bérard, Audrey Bidet et autres

Abstract Acute myeloid leukemia (AML) with t(9;22) (q34.1; q11.2)/ BCR::ABL1 , a distinct entity within the group of AML with defining genetic abnormalities, belong to the adverse-risk group of the 2022 ELN classification. However, there is little data on outcome since the …

fr (code pays fourni par la source)

Impact de la Lévofloxacine en prophylaxie primaire dans l'incidence de neutropénie fébrile chez les patients traités par Azacitidine Venetoclax pour une leucémie aiguë myéloïde.

Nicolas Rasandisona, X. Brousse, Karen Delavigne, S. Tavitian et autres

fr (code pays fourni par la source)

Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study.

Christian Récher, Camille Gondran, Pierre‐Yves Dumas, Emilie Bérard et autres

fr, ca (code pays fourni par la source)